扩散加权MRI与[18F]FDG PET/MRI在儿童霍奇金和非霍奇金淋巴瘤治疗监测中的比较
回顾性单中心研究纳入45例儿童及年轻霍奇金淋巴瘤(n=20)和非霍奇金淋巴瘤(n=25)患者,比较全身扩散加权成像(WB-DWI)与[18F]FDG PET/MRI按Lugano标准和WB-DWI改良标准评估诱导化疗后及治疗结束时的反应。霍奇金淋巴瘤两种方法一致性高(Gwet's AC=0.94),非霍奇金淋巴瘤一致性较低(Gwet's AC=0.66);治疗结束时所有类型一致性极好(Gwet's AC=0.97)。
要点
- 霍奇金淋巴瘤诱导化疗后WB-DWI与PET/MRI反应评估一致性高(Gwet's AC=0.94)。
- 非霍奇金淋巴瘤诱导化疗后两种方法一致性较低(Gwet's AC=0.66)。
- 治疗结束时所有淋巴瘤类型两种方法反应评估一致性极好(Gwet's AC=0.97)。
核心结论
- 霍奇金淋巴瘤的治疗反应可用[18F]FDG PET或WB-DWI评估,而非霍奇金淋巴瘤患者可能受益于联合方法。
研究设计与样本
- 回顾性、非随机、单中心研究,纳入2018年2月至2022年10月间45例儿童及年轻患者(27例男性;平均年龄13岁±5岁,范围1-21岁),其中霍奇金淋巴瘤20例、非霍奇金淋巴瘤25例。
关键影像表现/征象
- 测量最多6个靶病灶的最小表观扩散系数(ADCmin)和最大标准化摄取值(SUVmax)。
- 诱导化疗后,霍奇金淋巴瘤中95%(19/20)患者肿瘤代谢与质子扩散反应一致。
- 诱导化疗后,非霍奇金淋巴瘤中72%(18/25)患者肿瘤代谢与质子扩散反应一致。
诊断标准与关键数值
- 按Lugano标准和WB-DWI改良标准评估治疗反应。
- 霍奇金淋巴瘤WB-DWI与[18F]FDG PET/MRI反应分类一致性Gwet's AC=0.94(95%CI:0.82,1.00)。
- 非霍奇金淋巴瘤WB-DWI与[18F]FDG PET/MRI反应分类一致性Gwet's AC=0.66(95%CI:0.43,0.90)。
- 治疗结束后WB-DWI与[18F]FDG PET/MRI反应评估一致性Gwet's AC=0.97(95%CI:0.91,1)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare tumor therapy response assessments with whole-body diffusion-weighted imaging (WB-DWI) and 18F-fluorodeoxyglucose ([18F]FDG) PET/MRI in pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma.
MATERIALS AND METHODS: In a retrospective, non-randomized single-center study, we reviewed serial simultaneous WB-DWI and [18F]FDG PET/MRI scans of 45 children and young adults (27 males; mean age, 13 years ± 5 [standard deviation]; age range, 1-21 years) with Hodgkin lymphoma (n = 20) and non-Hodgkin lymphoma (n = 25) between February 2018 and October 2022. We measured minimum tumor apparent diffusion coefficient (ADCmin) and maximum standardized uptake value (SUVmax) of up to six target lesions and assessed therapy response according to Lugano criteria and modified criteria for WB-DWI. We evaluated the agreement between WB-DWI- and [18F]FDG PET/MRI-based response classifications with Gwet's agreement coefficient (AC).
RESULTS: After induction chemotherapy, 95% (19 of 20) of patients with Hodgkin lymphoma and 72% (18 of 25) of patients with non-Hodgkin lymphoma showed concordant response in tumor metabolism and proton diffusion. We found a high agreement between treatment response assessments on WB-DWI and [18F]FDG PET/MRI (Gwet's AC = 0.94; 95% confidence interval [CI]: 0.82, 1.00) in patients with Hodgkin lymphoma, and a lower agreement for patients with non-Hodgkin lymphoma (Gwet's AC = 0.66; 95% CI: 0.43, 0.90). After completion of therapy, there was an excellent agreement between WB-DWI and [18F]FDG PET/MRI response assessments (Gwet's AC = 0.97; 95% CI: 0.91, 1).
CONCLUSION: Therapy response of Hodgkin lymphoma can be evaluated with either [18F]FDG PET or WB-DWI, whereas patients with non-Hodgkin lymphoma may benefit from a combined approach.
CLINICAL RELEVANCE STATEMENT: Hodgkin lymphoma and non-Hodgkin lymphoma exhibit different patterns of tumor response to induction chemotherapy on diffusion-weighted MRI and PET/MRI.
KEY POINTS: • Diffusion-weighted imaging has been proposed as an alternative imaging to assess tumor response without ionizing radiation. • After induction therapy, whole-body diffusion-weighted imaging and PET/MRI revealed a higher agreement in patients with Hodgkin lymphoma than in those with non-Hodgkin lymphoma. • At the end of therapy, whole-body diffusion-weighted imaging and PET/MRI revealed an excellent agreement for overall tumor therapy responses for all lymphoma types.
引用
- Morakote W, Baratto L, Ramasamy SK, et al. Comparison of diffusion-weighted MRI and [18F]FDG PET/MRI for treatment monitoring in pediatric Hodgkin and non-Hodgkin lymphoma. Eur Radiol. 2023. PMID: 37542653. doi:10.1007/s00330-023-10015-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。